EMEA-003080-PIP03-22
- Active Substance
Vilobelimab
- Therapeutic area
Infectious diseases
- Decision number
P/0118/2023
- PIP number
EMEA-003080-PIP03-22
- Pharmaceutical form(s)
Concentrate for solution for infusion
- Condition(s) / indication(s)
Treatment of Coronavirus disease 2019 (COVID-19)
- Route(s) of administration
Intravenous use
- Contact for public enquiries
- Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
- Decision date
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
